After Radiation for DCIS, No Increase in Cardiovascular Mortality, Morbidity

Article

The exposure of the heart to radiation during radiotherapy for ductal carcinoma in situ (DCIS) did not increase cardiovascular mortality or morbidity, according to a study by researchers in the Netherlands.

SAN FRANCISCO-The exposure of the heart to radiation during radiotherapy for ductal carcinoma in situ (DCIS) did not increase cardiovascular mortality or morbidity, according to a study by researchers in the Netherlands. In fact, compared to the general population, these women had a decreased risk of cardiovascular death.

The data, taken from a study of more than 10,000 women with DCIS, were presented by Naomi M. Boekel, PhD candidate at the Netherlands Cancer Institute, Amsterdam, at the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 2013.

“After a median follow-up duration of 10 years, DCIS patients had a lower risk of cardiovascular mortality, independent of treatment and had no increased risk for cardiovascular morbidity or mortality after radiotherapy for DCIS compared to surgery only,” Dr. Boekel said.

Women with DCIS interested in breast conservation often undergo both surgical resection of their cancer and radiation therapy. When patients undergo left-sided radiotherapy, the heart is in the radiation field; whereas, right-sided radiotherapy only exposes the heart to scattered radiation.

Although previous studies have shown that radiation to the heart increases the risk of cardiovascular diseases, radiation to the heart during DCIS is relatively low, Dr. Boekel said. However, the question of whether patients with DCIS have increased cardiovascular mortality or morbidity was worth exploring.

Dr. Boekel and colleagues conducted a large population-based study of 10,468 women with incident DCIS diagnosed between 1989 and 2004. All women were aged younger than 75 years and had a median follow-up of 10 years.

All-cause mortality was similar between patients with DCIS and the general population. In contrast, 5-year survivors of DCIS had a 30% lower risk of dying of cardiovascular disease compared with the general population (standardized mortality ratio = 0.77; 95% CI, 0.67–0.89).

“This lower risk might be due to lifestyle adaption after DCIS diagnosis,” Dr. Boekel posited. “It could also be due to conflicting risk factors between DCIS and cardiovascular disease such as age at menopause, or it could be due to differences in health consciousness.”

The researchers also compared cardiovascular outcomes among the women with DCIS by treatment group: surgery, right-handed radiotherapy and left-sided radiotherapy. Similar results were seen for mortality and morbidity from cardiovascular diseases between all treatment groups.

“Although these results are reassuring, longer follow-up is necessary before definite conclusions can be drawn,” Dr. Boekel said.

Commenting on the study, Steven O’Day, MD, director of clinical research at the Beverly Hills Cancer Institute, said that older radiation studies clearly showed a correlation between radiation and cardiovascular toxicity when the fields were overlapping with the heart.

“However, since then, radiation therapy has been refined,” he said.

This study should be reassuring to oncologists and should allow them to feel comfortable continuing aggressive treatment of DCIS, O’Day added.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content